JAKARTA, INDONESIA--(Marketwire - Sep 13, 2012) - Moments ago, Investors-Alliance.com introduced new coverage of Cell Therapeutics, Inc. (
The consistent delivery of accurate analyses relies solely on two factors, namely: market awareness and industry insight. Recent market drivers include August's contraction of U.S. manufacturing activity, an upward surprise of 0.4% in seasonally-adjusted house prices and the unexpected decline in construction spending. When it comes to discovering the right edge at the right time, all these factors play into effect. For a deeper understanding of the mechanics behind these events and how it can affect your portfolio, please refer to our email newsletter delivered to your inbox.
Investors Alliance is releasing new coverage on Cell Therapeutics, Inc. for its current position within the consumer durables sector. Cell Therapeutics, Inc. (CTI) develops, acquires and commercializes treatments for cancer. The Company's research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. A copy of this report featuring Cell Therapeutics, Inc. (
Investors Alliance has released research on Novartis AG for its changing role within the consumer durables sector. Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. To access the full research report on Novartis AG (
What is Investors Alliance?
Imagine a community wherein investors and traders of all walks share both knowledge and experience... enabling a knowledge base vastly greater than the sum of its parts. By joining forces, the entire community experiences the wealth of information, insight and intuition into some of the best strategies available today.
- Novartis AG